Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (Glenmark) an integrated research-led global pharmaceutical company reaffirms its commitment to sustainability by joining the esteemed Science Based Targets initiative (SBTi) business ambition for well below 2°C. The SBTis has approved Glenmarks commitment to reduce its absolute scope 1 and 2 GHG emissions by 35% (from a FY2021 base year) by FY2035. The target boundary includes biogenic land-related emissions and removals from bioenergy feedstock. The approval also extends to our pledge to reduce scope 3 GHG emissions from purchased goods and services fuel and energy related activities downstream transportation and distribution and investments by 28% per ton of pharmaceutical products within the same timeframe.Glenmark got certified following a rigorous 5-stage review and is only the second Indian Pharmaceutical company to receive this approval.